Lab
DX Solutions, LLC
DX Solutions, LLC was paid $24.89M by Medicaid between Apr 2018 and Dec 2024, across 174 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 52% of everything it billed.
33Billing provider infoDX SOLUTIONS, LLC
NICHOLASVILLE, KY 40356
NICHOLASVILLE, KY 40356
33aNPI1114435492assigned 01/20/2018
33bProvider typeClinical Medical Laboratory
28Total paid$24.89M
24GClaims1,348,685
24DCodes billed174
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Kentucky
Rank by total paid#6 of 73
Median peer was paid$95K
This provider vs. median262×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,586 | $653K | |
| 2019 | 23,869 | $1.55M | |
| 2020 | 207,292 | $6.85M | |
| 2021 | 372,417 | $7.83M | |
| 2022 | 268,788 | $4.63M | |
| 2023 | 247,446 | $1.85M | |
| 2024incomplete | 221,287 | $1.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 52% | 369,511 | 168,394 | $13.02M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 13% | 26,966 | 23,243 | $3.29M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 9.5% | 217,258 | 99,043 | $2.35M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.8% | 5,490 | 4,942 | $1.19M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 6,126 | 5,821 | $373K |
| 80074 | 1.0% | 15,193 | 14,013 | $256K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25,263 | 23,015 | $237K |
| 87481 | <1% | 7,920 | 6,851 | $208K | |
| 80053 | Comprehensive metabolic panel | <1% | 64,451 | 56,417 | $207K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 36,081 | 32,530 | $192K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,981 | 64,032 | $174K |
| 87640 | <1% | 12,033 | 10,653 | $170K |
162 more codes
| 87581 | <1% | 9,124 | $162K | |
| 87507 | <1% | 1,122 | $159K | |
| 87486 | <1% | 8,833 | $157K | |
| 80061 | Lipid panel | <1% | 33,349 | $149K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,119 | $130K |
| 87653 | <1% | 8,548 | $129K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,211 | $122K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 10,937 | $120K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,727 | $118K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,642 | $116K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,636 | $105K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 34,042 | $102K |
| 82607 | <1% | 19,078 | $98K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,435 | $80K |
| 87563 | <1% | 4,873 | $77K | |
| 87498 | <1% | 5,107 | $75K | |
| 87632 | <1% | 1,139 | $73K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,627 | $73K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,511 | $69K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,098 | $63K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,502 | $58K |
| 86480 | <1% | 1,637 | $49K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 49,183 | $41K |
| 87186 | <1% | 3,919 | $41K | |
| 80047 | <1% | 13,710 | $38K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 31,234 | $38K |
| 82746 | <1% | 6,316 | $34K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 537 | $31K |
| 80050 | General health panel | <1% | 1,456 | $30K |
| 84439 | <1% | 8,969 | $30K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,131 | $28K |
| 87641 | <1% | 1,770 | $28K | |
| 87529 | <1% | 981 | $27K | |
| 86703 | <1% | 4,258 | $27K | |
| 84481 | <1% | 3,819 | $25K | |
| 82728 | <1% | 4,934 | $24K | |
| 87511 | <1% | 1,231 | $20K | |
| 84403 | <1% | 1,864 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,805 | $19K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,044 | $18K |
| 83880 | <1% | 2,192 | $18K | |
| 87631 | <1% | 422 | $17K | |
| 84153 | <1% | 2,768 | $17K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 285 | $17K |
| 83540 | <1% | 7,031 | $15K | |
| 83735 | <1% | 7,346 | $15K | |
| 82670 | <1% | 1,329 | $15K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 27,212 | $14K |
| 80164 | <1% | 4,425 | $13K | |
| 84402 | <1% | 1,220 | $12K | |
| 87902 | <1% | 111 | $11K | |
| 83550 | <1% | 4,131 | $11K | |
| 85027 | <1% | 4,863 | $11K | |
| 87501 | <1% | 1,001 | $10K | |
| 81003 | <1% | 13,458 | $10K | |
| 86803 | <1% | 1,943 | $8K | |
| 84144 | <1% | 959 | $8K | |
| 83001 | <1% | 983 | $7K | |
| 83970 | <1% | 753 | $7K | |
| 87088 | <1% | 2,952 | $7K | |
| 86376 | <1% | 1,005 | $7K | |
| 84466 | <1% | 1,357 | $7K | |
| 87541 | <1% | 344 | $6K | |
| 83525 | <1% | 1,146 | $6K | |
| 86592 | <1% | 2,723 | $6K | |
| 85610 | <1% | 6,140 | $5K | |
| 87070 | <1% | 1,791 | $5K | |
| 83002 | <1% | 723 | $5K | |
| 80076 | <1% | 3,229 | $5K | |
| 80177 | <1% | 1,643 | $5K | |
| 86141 | <1% | 1,034 | $4K | |
| 86593 | <1% | 1,968 | $4K | |
| 82627 | <1% | 361 | $4K | |
| 84702 | <1% | 475 | $3K | |
| 87506 | <1% | 60 | $3K | |
| 86705 | <1% | 911 | $3K | |
| 82043 | <1% | 1,946 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 103 | $3K |
| 84436 | <1% | 1,882 | $3K | |
| 86140 | <1% | 1,623 | $3K | |
| 86780 | <1% | 466 | $3K | |
| 84270 | <1% | 412 | $3K | |
| 84480 | <1% | 956 | $3K | |
| 84146 | <1% | 362 | $3K | |
| 87500 | <1% | 316 | $3K | |
| 82570 | <1% | 1,443 | $2K | |
| 86038 | <1% | 444 | $2K | |
| 80178 | <1% | 1,022 | $2K | |
| 87340 | <1% | 783 | $2K | |
| 82533 | <1% | 278 | $2K | |
| 86800 | <1% | 260 | $2K | |
| 87280 | <1% | 1,019 | $2K | |
| 82553 | <1% | 360 | $2K | |
| 86431 | <1% | 744 | $2K | |
| 85651 | <1% | 1,345 | $2K | |
| 82248 | <1% | 806 | $2K | |
| 86709 | <1% | 562 | $2K | |
| 84703 | <1% | 409 | $2K | |
| 87493 | <1% | 228 | $2K | |
| 83690 | <1% | 576 | $2K | |
| 82550 | <1% | 622 | $1K | |
| 86708 | <1% | 249 | $1K | |
| 82150 | <1% | 546 | $1K | |
| 84165 | <1% | 411 | $1K | |
| 82140 | <1% | 420 | $1K | |
| 87634 | <1% | 117 | $1K | |
| 84550 | <1% | 1,155 | $1K | |
| 85652 | <1% | 1,147 | $1K | |
| 80069 | <1% | 710 | $1K | |
| 86696 | <1% | 121 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 105 | $1K |
| 82565 | <1% | 1,205 | $1K | |
| 86702 | <1% | 135 | $813.76 | |
| 86695 | <1% | 126 | $808.67 | |
| 80185 | <1% | 399 | $797.81 | |
| 84134 | <1% | 302 | $716.39 | |
| 84156 | <1% | 479 | $653.22 | |
| 80202 | <1% | 233 | $643.77 | |
| 80175 | <1% | 144 | $580.28 | |
| 86701 | <1% | 142 | $562.92 | |
| 84681 | <1% | 64 | $543.43 | |
| 84105 | <1% | 419 | $528.71 | |
| 84132 | <1% | 527 | $504.04 | |
| 86328 | <1% | 115 | $473.06 | |
| 86677 | <1% | 60 | $454.63 | |
| 84252 | <1% | 55 | $397.58 | |
| 82465 | <1% | 211 | $383.07 | |
| 87503 | <1% | 806 | $347.09 | |
| 80156 | <1% | 115 | $337.22 | |
| 82274 | <1% | 87 | $279.94 | |
| 82040 | <1% | 520 | $273.45 | |
| 80165 | <1% | 98 | $267.91 | |
| 84479 | <1% | 419 | $266.78 | |
| 82950 | <1% | 142 | $262.06 | |
| 80162 | <1% | 158 | $246.70 | |
| 87077 | <1% | 80 | $238.33 | |
| 84155 | <1% | 499 | $231.26 | |
| 84100 | <1% | 165 | $225.42 | |
| 82977 | <1% | 94 | $223.91 | |
| 85018 | <1% | 343 | $220.63 | |
| 81001 | <1% | 227 | $187.82 | |
| 81025 | <1% | 39 | $182.64 | |
| 83721 | <1% | 246 | $157.71 | |
| 86706 | <1% | 30 | $137.26 | |
| 82947 | <1% | 222 | $129.57 | |
| 86704 | <1% | 27 | $124.71 | |
| 84520 | <1% | 137 | $121.12 | |
| 85045 | <1% | 98 | $104.78 | |
| 84460 | <1% | 63 | $102.36 | |
| 84154 | <1% | 14 | $91.39 | |
| 87205 | <1% | 49 | $82.15 | |
| 83615 | <1% | 29 | $71.15 | |
| 84450 | <1% | 34 | $38.50 | |
| 84295 | <1% | 49 | $33.93 | |
| 80051 | <1% | 44 | $29.57 | |
| 85014 | <1% | 80 | $24.68 | |
| 82310 | <1% | 18 | $9.80 | |
| 81015 | <1% | 16 | $6.07 | |
| 82247 | <1% | 49 | $5.98 | |
| 82435 | <1% | 16 | $4.60 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 40 | $0.00 |
| 87807 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIDHU, PREETPAL (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Choice Diagnostic Lab | Southlake, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.